ZBIOZenas BioPharma, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (BB) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -75% · now 38% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ZBIO take a bad year?
Zenas BioPharma, Inc. holds $420M more cash than debt, and is burning $56M a quarter, about 2.9 years of cover.
Net cash · as at Q2 2026 · cash and short-term investments less total debt
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 2.27
Altman Z-score · grey zone, between 1.8 and 3
- Cash runway
- 2.9 years
Cash runway · burning $56M a quarter at the current rate
Details›
- Total debtQ2 2026
- $223M
- Cash and short-term investments
- $643M
- Net cash
- $420M
- EBITDA, trailing twelve months
- −$476M
- Operating profit, trailing twelve months
- −$476M
- Debt / equity
- 0.90×
- Annualised volatilitytwo years of daily moves
- 104%
- Worst drawdown on file
- −75%
- Below its 52-week high
- 38%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.
Biotechnology
The closest names by size in the same industry